HIV Prevention

For 340B-covered entities, core to the challenge of navigating a changing and uncertain policy landscape is the complexity of how multiple variables interact differently with each covered health care entity based on its unique makeup of services, funding, patient population, and payer mix. This toolkit aims to assist 340B covered entities in understanding their current areas of funding stability and where they are vulnerable, and to plan for the future.

In light of proposed and actual changes in Federal and State policy that have the potential to affect the 340B program, we conducted a rapid response study, exploring the impact to facilities that serve people living with or at risk for HIV. As a companion to the Navigating 340B Toolkit, this Explainer takes a closer look at the answers to these three questions: 1. How does 340B work? 2. What is the relationship between 340B and HIV services? 3. What are the current factors impacting 340B revenue for HIV clinical and service organizations?

A new paper published in JAIDS finds that pharmacists could play a key role in providing long-acting injectable pre-exposure prophylaxis (PrEP) for HIV prevention. In a mixed methods analysis of survey and interview data, CHPRC researchers found that many pharmacists would be willing to administer injectable PrEP if provided with training, compensation, and a private room. However, pharmacists may require additional resources and policy support to make widespread implementation feasible.

The Support Academic Futures & Educators for Today’s Youth (SAFETY) Act prohibits school boards from requiring the forced outing of LGBTQA+ youth in school settings. Critical protections includes newly passed SAFETY Act and others established rights under U.S. and California law.

Policy brief based on a study of seven California emergency departments (ED) implementing HIV Prevention Services (HPS) linkage programs. Three models for integrating HPS into the ED were identified and may serve as a guide for future protocol development.

In February 2024, Senate Bill 339 was signed into law to help realize the goal of widespread access to HIV pre- and post-exposure prophylaxis (PrEP and PEP) in California pharmacies. This fact sheet explains key changes under Senate Bill 339 that may reduce previously-identified barriers to pharmacist delivery of PrEP/PEP.

There were 4,444 HIV diagnosis in California in 2021. Of those, 12% were among women. Black/African American and Latinx are disproportionately impacted.

Paper A Systematic Review of HIV Pre-exposure Prophylaxis (PrEP) Implementation in U.S. Emergency Departments: Patient Screening, Prescribing, and Linkage to Care January 18, 2024 Systematic Review of peer-reviewed quantitative studies and conference abstracts addressing PrEP screening, prescribing, and/or linkage to PrEP care in US Emergency Departments. Further research into the best practices for integrating ED […]

Infographic 2021 COVID-19 Organizational Health Survey June 13, 2022 In the fall of 2021, the California HIV/AIDS Policy Research Centers conducted an online survey to document the direct impact of COVID-19 on healthcare and social services providers working to address HIV, viral hepatitis and sexually transmitted infections (STIs). Survey respondents included 30 organizations that submitted […]